Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
暂无分享,去创建一个
M Schwaiger | M. Schwaiger | S. Ziegler | W. Weber | C. Nerl | W. Römer | M. Herz | W Römer | S Ziegler | A. Hanauske | R. Thödtmann | C. Fuchs | W. Enne | M. Garbrecht | R Thödtmann | A R Hanauske | W Weber | C Nerl | M Herz | C Fuchs | W Enne | M Garbrecht | Wolfgang A. Weber | Markus Schwaiger | Christoph Nerl | S. Ziegler | Wolfgang Römer | Axel-R. Hanauske | Ralf Thödtmann | Christoph Fuchs | Wolfgang Enne | Michael Herz | Manfred Garbrecht | C. Nerl | M. Schwaiger
[1] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] T. Fukumura,et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] R. Fisher. Treatment of aggressive non‐hodgkin's lymphomas: Lessons from the past 10 years , 1994 .
[4] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R L Wahl,et al. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] U Ruotsalainen,et al. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] R L Wahl,et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.
[9] R L Wahl,et al. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.
[10] K. Någren,et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] H. Minn,et al. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] A. D. Van den Abbeele,et al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] Otto Warburn,et al. THE METABOLISM OF TUMORS , 1931 .
[14] G. Canellos,et al. Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.
[16] B. Leber,et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M Schwaiger,et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] B. Glimelius,et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] G. van Kaick,et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] J. Tabernero,et al. CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma. , 1994, Acta oncologica.
[21] D. Neuberg,et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L M Hamberg,et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] G. van Kaick,et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[26] M. Phelps,et al. Quantitating tumor glucose metabolism with FDG and PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] R. Hardoff,et al. Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] J. Cosset,et al. Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] H. Minn,et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.
[30] H C Charles,et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] David J. Yang,et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] A. Oguz,et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] L G Strauss,et al. The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] K. Ishiwata,et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of Nuclear Medicine.
[35] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[36] O. Hoekstra,et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] N. Alpert,et al. FDG-PET in oncology: there's more to it than looking at pictures. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] J. Armitage,et al. What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas? , 1993, Leukemia & lymphoma.
[39] E. Rota Kops,et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] U Ruotsalainen,et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.